| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Shenzhen Kangtai Biological Products Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥20.45 |
| 52 Week High | CN¥34.18 |
| 52 Week Low | CN¥18.44 |
| Beta | 0.73 |
| 1 Month Change | -15.46% |
| 3 Month Change | -15.43% |
| 1 Year Change | -36.96% |
| 3 Year Change | -76.05% |
| 5 Year Change | -39.09% |
| Change since IPO | -51.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300601 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -4.6% | -1.9% | -0.2% |
| 1Y | -37.0% | -26.9% | -17.8% |
Return vs Industry: 300601 underperformed the CN Biotechs industry which returned -29.3% over the past year.
Return vs Market: 300601 underperformed the CN Market which returned -21.1% over the past year.
Price Volatility
| 300601 volatility | |
|---|---|
| 300601 Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 300601 has not had significant price volatility in the past 3 months.
Volatility Over Time: 300601's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 2,018 | Xiang Miao | www.biokangtai.com |
Shenzhen Kangtai Biological Products Co., Ltd. researches, develops, produces, and sells various types of human vaccines in China. The company’s products include cell-free whitebait b-type haemophilus influenzae combined vaccine, SARS-COV-2 vaccine, recombinant hepatitis B vaccine, 23-valent pneumococcal polysaccharide vaccine, diphtheria tetanus acellular pertussis and haemophilus influenzae type b combined vaccine, haemophilus influenzae type b conjugate vaccine, measles and rubella combined vaccine, 13-valent pneumococcal conjugate vaccine, rabies vaccine, inactivated poliomyelitis vaccine, live attenuated varicella vaccine, and HIB conjugate vaccine.
Shenzhen Kangtai Biological Products Co., Ltd. Fundamentals Summary
| 300601 fundamental statistics | |
|---|---|
| Market cap | CN¥22.84b |
| Earnings (TTM) | CN¥361.20m |
| Revenue (TTM) | CN¥3.06b |
63.2x
P/E Ratio7.5x
P/S RatioIs 300601 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300601 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.06b |
| Cost of Revenue | CN¥786.04m |
| Gross Profit | CN¥2.27b |
| Other Expenses | CN¥1.91b |
| Earnings | CN¥361.20m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 27, 2024
| Earnings per share (EPS) | 0.32 |
| Gross Margin | 74.29% |
| Net Profit Margin | 11.82% |
| Debt/Equity Ratio | 25.2% |
How did 300601 perform over the long term?
See historical performance and comparison